PepGen (PEPG) Research Hub

PepGen (PEPG) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.49 USD (-1.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.99, market cap 0.14B. This hub links to the full technical, earnings and options research available for PEPG.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close2.49 USD (-1.19%)
52-week range1.49 USD – 3.57 USD
Trend regimeRange
14-day RSI55.6 (Bullish)
Trailing P/E-0.99
Market cap0.14B
Dividend yield0.00%
Next earnings2026-08-06

Available research for PEPG

Earnings

PEPG earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -0.99. Updated 2026-07-23.

Options: Covered Call

Covered Call on PEPG: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on PEPG: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on PEPG: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

PEPG technical analysis: range, last 2.49 USD, RSI 55.6, 52w range 1.49 USD–3.57 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is PEPG in?

PepGen (PEPG) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is PEPG in an uptrend or downtrend?

As of 2026-10-26, PEPG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is PEPG's trailing P/E ratio?

PEPG's trailing P/E is -0.99, with a market cap of 0.14B. See the earnings research page for full valuation detail.

When does PEPG next report earnings?

PEPG is next scheduled to report earnings on 2026-08-06.